Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Some people are apparently under the impression that prostate cancer is a “modern” cancer and that there is no evidence of this disease in earlier times. We can assure you that this is not the case.
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: case, earliest, Scythian king | 3 Comments »
A new report from researchers at the University of Florida Proton Therapy Institute offers us some additional information on the short-term outcomes of first-line treatment with image-guided proton beam radiation therapy (PBRT) for localized prostate cancer.
Filed under: Management, Treatment | Tagged: localized, outcome, PBRT, proton beam radiation | Leave a Comment »
On December 23, the National Cancer Institute (NCI) issued a media release announcing a first step toward major changes in how big, cooperative clinical trials get managed and funded in the USA.
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: clinical trials, cooperative, National Cancer Institute, policy, process | Leave a Comment »
The proposed list of complications as a consequence of androgen deprivation therapy (ADT) for advanced prostate cancer has just been increased.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, age, androgen deprivation therapy, cataracts, risk | Leave a Comment »
The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions.
Filed under: Diagnosis, Management, Treatment | Tagged: choice, first line, intermediate, localized, low, Management, patient, risk, Treatment | 2 Comments »
In July this year, we commented on the 14-year mortality data published by Hugosson et al. from the randomized, population-based, prostate cancer screening trial initiated in Göteborg, Sweden, in 1995.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: erectile dysfunction, incontinence, morbidity, radical prostatectomy, screening, side effects | 2 Comments »
A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, survival, T, testosterone | 3 Comments »
A new report from a French research team has provided detailed 5-year data on the oncological outcomes of a series of low- and intermediate-risk prostate cancer patients treated with high-intensity ultrasound (HIFU) using second-generation Ablatherem™ equipment.
Filed under: Management, Treatment, Uncategorized | Tagged: HIFU, high-intensity focused ultrasound, outcome | Leave a Comment »
There is no consensus about the appropriateness of widespread testing for risk of prostate cancer. While many guidelines recommend that primary care physicians have a structured conversation with their male patients about the appropriateness of such testing, we had not (before today) come across any sound guidance for the primary care community about how to have that discussion.
Filed under: Uncategorized | Tagged: discussion, doctor, patient, primary care, screening, testing | Leave a Comment »
Whether there is any real association (let alone a cause and effect correlation) between clinically evident or subclinical inflammatory disorders and risk for prostate cancer is still not known — although long suspected.
Filed under: Diagnosis, Risk | Tagged: inflammation, marker, risk | Leave a Comment »
On Tuesday this week, an article appeared on the widely-read Politico web site entitled “The politics of prostate cancer.” It was based on the recent surgical treatment of U.S. Senator Ron Wyden. And it included some rather odd statements.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, invasive treatment, politics, surgery, Wyden | Leave a Comment »
The adverse effects of androgen deprivation therapy (ADT) resulting from the use of surgical castration (orchiectomy) or medical castration (luteinizing hormone-releasing hormone [LHRH] agonists) are extensive, including sexual dysfunction, hot flashes, osteoporosis, and many others.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse effects, androgen deprivation, estogen | Leave a Comment »
Prospective data from a significant Spanish study provide us with additional insights into the short- and longer-term adverse effects of common types of invasive therapy for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse effects, external beam radiation, first line, radical prostatectomy, surgery | 2 Comments »
Among prostate cancer specialists, there has been a broad acceptance — for some time — of the idea that a localized prostate cancer “index” tumor with a Gleason score of 6 or less and a volume of ≤ 0.5 cm3 could be considered to be clinically insignificant and therefore did not (necessarily) need to be treated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: clinical insignificance, clinical significance, Gleason grade, Management, staging, tumor volume | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site